ABSTRACT Exonuclease mI has been shown previously to reveal the binding sites of the antitumor drug cis-diamminedichloroplatinum(II) on DNA. Pretreatment of the same DNA with the intercalator ethidium bromide causes new platinum binding sites to be detected by the exonuclease m method. In particular, a 5' d(G6-C-G2) 3' sequence in a 165-base-pair restriction fragment of plasmid pBR322 becomes a preferred site for exonuclease mIdetectable cis-diamminedichloroplatinum(II) binding. This switching of nuclease-sensitive platinum binding to new sites by the influence of another drug, ethidium bromide, offers an explanation at the molecular level for the phenomenon of synergism in combination chemotherapy.
cis-Diamminedichloroplatinum(II) (cis-DDP), .a powerful antitumor agent, is generally used with other drugs in combination chemotherapy (1) . There is much evidence that DNA is the biological target for cis-DDP (2) as well as for other anticancer drugs. We recently developed a method for determining the nuclease-sensitive positions of cis-DDP bound to a known sequence of DNA (3) by using exonuclease III (4) digestion along with DNA sequence determination techniques (5) .
We now report that ethidium bromide, a compound known to bind to DNA by intercalation (6) , can change the sites on a DNA molecule where the exonuclease III method detects covalent binding ofcis-DDP. Intercalating drugs such as adriamycin are often used in chemotherapy with cis-DDP (1). Our results therefore offer a possible rationale at the molecular level for the synergism found for drugs used in combination with cis-DDP. We suggest that the DNA binding properties of the platinum drug might depend on the presence ofanother drug, in contrast to the more common explanation of combination chemotherapy which proposes independent action of two drugs-for example, at different phases in the cell cycle.
EXPERIMENTAL
Preparation of Labeled DNA. The singly end-labeled 165-base-pair (bp) DNA molecule (3) used in these experiments was prepared by digestion of plasmid pBR322 with the restriction endonuclease Hpa II (Bethesda Research Laboratories) and isolation of the second largest fragment, 527 bp, from a preparative agarose electrophoresis gel. Bacterial alkaline phosphatase (Bethesda Research Laboratories) was used to remove 5'-phosphates (5 The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact.
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Biochemistry: Tullius and Lippard graphs was performed with a Beckman DU-8 slab gel scanning system. RESULTS AND DISCUSSION Our recent studies (3) , as well as independent work by Haseltine and co-workers (8) , used singly end-labeled DNA molecules of known sequence as substrates for platinum binding. Bound cis-DDP causes new products to appear in an exonuclease III digestion of the DNA. This enzyme has both 3' exonuclease and apurinic/apyrimidinic endonuclease activities. The sites ofplatination sensed by exonuclease III can be revealed by subjecting the digestion products to electrophoresis through a polyacrylamide/7 M urea DNA sequencing gel (5, 7). DNA fragments generated by the Maxam-Gilbert DNA sequence method (5) and electrophoresed in parallel are used as molecular "rulers" to identify the particular bases at which platination stops exonuclease III digestion. Both our experiments (3) and those of Has-1 23 4 56 eltine and co-workers (8) showed that exonuclease III detects cis-DDP binding to oligo(dG) sites. This result is evident in lanes 1 and 8 of Fig. 1 where strong bands are seen corresponding to platinum binding at dG5, dG3, and dG2 sequences in a 165-bp DNA molecule. An anomaly in this experiment was apparent to us, however. There is a 5' d(G6-C-G2) 3' sequence 29 bases from the 3' end of this DNA molecule (9) . Based on the postulated affinity of cis-DDP for oligo(dG) sequences (10) (11) (12) and the proximity of this site to the starting point of the 3'-exonucleolytic degradation of DNA by exonuclease III, we had expected a very strong band to be present corresponding to platination of the dG6 site. Yet only a relatively weakband was observed.
When the DNA molecule was incubated with ethidium bromide before the addition of cis-DDP, however, a dramatic change in the exonuclease III-detected platinum binding at the d(G6-C-G2) site was observed (lanes 2-5 and 9-12 in Fig. 1 ). The bands due to platination of the d (G6-C-G2 (1982) 3491 major bands in the autoradiographic pattern not seen in control digestions (lane 7). Control experiments showed that treatment of unplatinated DNA with ethidium bromide and subsequent removal of the drug by phenol extraction and ethanol precipitation had no effect on the exonuclease III digestion pattern.
To determine in more detail the effect of ethidium bromide on the d(G6-C-G2) bands, we ran aliquots ofthese same samples on a gel giving higher resolution (Fig. 2) . With no ethidium bromide present (lanes 1 and 8) , either no bands or only weak bands appeared as a result of platination of the dG6 region. With approximately four ethidium bromide molecules bound to the 165-bp DNA molecule (ethidium bromide D/N = 0.012) (lanes 2 and 9), distinct bands due to platination of the dG2 site were evident. The dG6 site still showed little effect on exonuclease III digestion. With more ethidium bromide present in the platination reaction mixture (lanes 3-5 and 10-12), more cis-DDP binding to the dG6 region was detected and binding to the dG2 site appeared to decrease relatively. This result implies that the effect of ethidium bromide is not simply to increase the overall level of platinum binding. Independent studies on the quantitation ofcis-DDP binding to plasmid pBR322 in the presence or absence ofethidium bromide have confirmed this conclusion (C. M. Merkel, personal communication).
A further characteristic of the ethidium bromide-promoted binding ofcis-DDP to the d(G6-C-G2) sequence is clear in e~~~^o the peak of intensity is at the G band at the 3' end of the dG6 sequence. The intensities of the remaining bands fall off smoothly toward the 5' end. What is the reason for this effect ofethidium bromide on the exonuclease III sensitive mode ofbinding ofcis-DDP to DNA? Several recent experiments have shown that the structure ofthe DNA double helix is not uniform-it varies with base sequence. Rich and co-workers (13) have found that d(CpGpCpGpCpG) crystallizes in a left-handed double-helical form, called Z-DNA, that is perhaps the most dramatic example of sequence-dependent DNA structure. The high-resolution x-ray crystallographic structure ofthe dodecanucleotide d (C-G-C-G-A-A-T-T-C-G-C-G) reported by Dickerson and Drew (14) shows another striking example of the variability oflocal DNA structure. Klug and coworkers have demonstrated that DNase I is sensitive to such structural variations (15) . The rate of DNase I cutting at a given phosphodiester bond of the dodecanucleotide depends on the twist angle ofthe adjacent bases, as seen in the crystal structure (14) . Other studies have reported sequence specificity in the digestion of DNA molecules by micrococcal nuclease (16, 17) . In fact, such sequence specificity of enzymatic activity can be seen in our exonuclease III experiments. Control digestions (Fig. 1, lane 7) of unplatinated 165-bp DNA give rise to several products in a highly reproducible distribution. Clearly, DNA processing enzymes can be affected by the local structure of DNA, which depends on the sequence.
The present results can be explained by assuming that the DNA binding ofthe antitumor drug cis-DDP is sensitive to local DNA structure. Ethidium bromide, upon intercalation, is known to unwind the DNA helix by 26°per bound drug mol- ecule (18) . This alteration of the local structure of DNA could account for the enhanced effect of cis-DDP on exonuclease III digestion at the d(G6-C-G2) site when ethidium bromide is present in the platination reaction mixture. Several experimentally testable possibilities come to mind. Ethidium bromide could bind selectively to certain regions of the DNA duplex (19) 
